Clinical Trial Update: A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock [Phase 2]

View source ↗

Summary

This document reports the results of a Phase 2 trial comparing two IV dosing regimens of AZD9773 (CytoFab) versus placebo in adults with severe sepsis and/or se…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• CytoFab (AZD9773)

Snippet

Sponsor: AstraZeneca | Conditions: Severe Sepsis, Septic Shock | Phase 2 | Status: COMPLETED | Results posted: 2013-09-23